Literature DB >> 31800049

Clinically significant drug interaction: letermovir and voriconazole.

Arianne Duong1,2, Ania Sweet2,3, Rupali Jain1,3,4, Joshua A Hill2,3,4,5, Steven A Pergam2,3,4,5, Michael Boeckh2,3,4,5, Catherine Liu2,3,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31800049      PMCID： PMC7021092          DOI： 10.1093/jac/dkz499

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  5 in total

1.  Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects.

Authors:  William L Marshall; Jacqueline B McCrea; Sreeraj Macha; Karsten Menzel; Fang Liu; Arne van Schanke; Joanna I Udo de Haes; Azra Hussaini; Heather R Jordan; Melissa Drexel; Bhavna S Kantesaria; Christine Tsai; Carolyn R Cho; Ellen G J Hulskotte; Joan R Butterton; Marian Iwamoto
Journal:  J Clin Pharmacol       Date:  2018-03-26       Impact factor: 3.126

2.  Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.

Authors:  Michael J Dolton; John E Ray; Sharon C-A Chen; Kingsley Ng; Lisa G Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

3.  Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.

Authors:  Francisco M Marty; Per Ljungman; Roy F Chemaly; Johan Maertens; Sanjeet S Dadwal; Rafael F Duarte; Shariq Haider; Andrew J Ullmann; Yuta Katayama; Janice Brown; Kathleen M Mullane; Michael Boeckh; Emily A Blumberg; Hermann Einsele; David R Snydman; Yoshinobu Kanda; Mark J DiNubile; Valerie L Teal; Hong Wan; Yoshihiko Murata; Nicholas A Kartsonis; Randi Y Leavitt; Cyrus Badshah
Journal:  N Engl J Med       Date:  2017-12-06       Impact factor: 91.245

4.  Adverse reactions to voriconazole.

Authors:  Aileen E Boyd; Simon Modi; Susan J Howard; Caroline B Moore; Brian G Keevil; David W Denning
Journal:  Clin Infect Dis       Date:  2004-09-23       Impact factor: 9.079

5.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

Authors:  Andres Pascual; Thierry Calandra; Saskia Bolay; Thierry Buclin; Jacques Bille; Oscar Marchetti
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079
  5 in total
  3 in total

Review 1.  Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation.

Authors:  Ajit P Limaye; Tara M Babu; Michael Boeckh
Journal:  Clin Microbiol Rev       Date:  2020-10-28       Impact factor: 26.132

2.  Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir.

Authors:  Jean Terrier; Marie-Céline Zanella; Stavroula Masouridi-Levrat; Ilona Kronig; Yves Chalandon; Nathalie Vernaz; Christian Van Delden; Genovefa Papanicolaou; Dionysios Neofytos
Journal:  Antimicrob Agents Chemother       Date:  2021-05-18       Impact factor: 5.191

Review 3.  Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.

Authors:  Morgan Hakki
Journal:  Curr Hematol Malig Rep       Date:  2020-04       Impact factor: 4.213
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.